To conduct a cost-effectiveness analysis (CEA) of a cobalt-chromium everolimus eluting stent (Co-Cr EES) versus BMS in PCI.Ī Markov state transition model with a 2-year time horizon was applied from a US Medicare setting with patients undergoing PCI with Co-Cr EES or BMS. We aimed to conduct an economic evaluation of a cobalt-chromium everolimus eluting stent (Co-Cr EES) compared with BMS in percutaneous coronary intervention (PCI). Second-generation drug eluting stents (DES) may reduce costs and improve clinical outcomes compared to first-generation DES with improved cost-effectiveness when compared to bare metal stents (BMS). 13 Department of Cardiology, University Hospital of Bern, Inselspital, Bern, Switzerland.12 Sussex Cardiac Centre, Thoraxcenter, Erasmus Medical Center, CE Rotterdam, Netherlands.11 Department of Cardiology, Brighton and Sussex University Hospitals, Brighton, UK.
10 Department of Cardiology, Stadtspital Triemli, Zurich, Switzerland.9 Heart Institute, University Hospital of Bellvitge, Barcelona, Spain.8 Department of Cardiology, Gentofte Hospital, Hellerup, Denmark.7 Interventional Cardiology Department, Hospital Marqués De Valdecilla, Santander, Spain.6 Department of Cardiology, University Hospital of Basel, Basel, Switzerland.5 Cardiology Department, University Hospital Clinic, IDIBAPS, Barcelona, Spain.4 Health Economics and Outcomes Research Department, Abbott Vascular and Abbott Electrophysiology, Santa Clara, CA.3 Health Economics and Outcomes Research Department, Abbott Vascular, Santa Clara, CA.2 Interventional Cardiology, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Rozzano, Italy.
0 kommentar(er)
